Abstract
The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analysis of Variance
-
Bombesin / analogs & derivatives*
-
Bombesin / pharmacology
-
Dose-Response Relationship, Drug
-
Enzyme-Linked Immunosorbent Assay
-
HT29 Cells
-
Humans
-
Nerve Growth Factor / metabolism*
-
Peptide Fragments / pharmacology*
-
Receptors, Bombesin / antagonists & inhibitors*
Substances
-
NGF protein, human
-
Peptide Fragments
-
Receptors, Bombesin
-
bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-
-
Nerve Growth Factor
-
Bombesin